Hereditary Cancer Genetic Screening Test: BRCA1/BRCA2, Lynch Syndrome, APC, and Results

Hereditary cancer genetic screening looks for inherited variants that can raise the chance of specific cancers across a lifetime. A multigene panel may include BRCA1 and BRCA2, the Lynch syndrome genes MLH1, MSH2, MSH6, PMS2, and EPCAM, the polyposis gene APC, and other genes selected from a person’s cancer history and family pattern. A positive result does not mean cancer is present or inevitable. It identifies a risk pathway that may change screening, preventive choices, treatment, and testing for relatives. A negative result can be strongly reassuring when it rules out a known family variant, but it may be less informative when no affected relative has been tested. Variants of uncertain significance should not drive surgery or intensive surveillance on their own. The most useful evaluation starts with the right person, the right panel, and a careful distinction between inherited germline testing and tumor-only biomarker testing.

• Hereditary cancer testing is most informative when an affected relative is tested first.
• BRCA1/BRCA2, Lynch syndrome, and APC cause different cancer patterns and require different surveillance plans.
• A pathogenic variant is a risk diagnosis, not proof that a person currently has cancer.
• Tumor sequencing can suggest an inherited variant but does not replace confirmatory germline testing.
• A true negative for a known familial variant is different from an uninformative negative panel.
• A VUS should not be used alone to recommend preventive surgery or test healthy relatives.

Table of Contents

• Who benefits from testing
• Three major syndrome patterns
• Choosing the right test
• Positive, negative, and VUS results
• Germline versus tumor testing
• What a positive result can change
• Family testing and reproductive risk
• Limits, privacy, and next steps

Who benefits from testing

Inherited pathogenic variants account for a minority of all cancers, but recognizing them can have an outsized effect on care. Testing may be appropriate for a person with cancer at an unusually young age, multiple primary cancers, a rare tumor type, a strong family pattern, numerous colon polyps, or tumor findings that suggest a hereditary syndrome. Current professional guidance also recommends broader germline testing for several common cancers than older family-history-only rules did.

Clues include:

• breast cancer at a young age, bilateral breast cancer, male breast cancer, ovarian or fallopian tube cancer, pancreatic cancer, or aggressive prostate cancer;
• colorectal or endometrial cancer with mismatch repair deficiency or microsatellite instability;
• colorectal cancer at a young age or multiple relatives with colorectal, endometrial, ovarian, gastric, urinary tract, or related cancers;
• tens to thousands of adenomatous colon polyps, duodenal polyps, desmoid tumors, or a family history of familial adenomatous polyposis;
• a known pathogenic variant in a biologic relative;
• ancestry associated with founder variants, while recognizing that ancestry alone should not restrict access to testing.

The best first person to test is usually an affected relative with the youngest or most syndrome-specific cancer. That person has the highest chance of revealing the family’s cause. If only an unaffected relative is available, testing can still be reasonable, but a negative result may not explain the family history.

A three-generation pedigree remains valuable even in the era of large panels. Record cancer type, age at diagnosis, whether paired organs were affected, pathology, polyp burden, and which side of the family each diagnosis is on. Maternal and paternal histories matter equally. BRCA1, BRCA2, Lynch syndrome genes, and APC are generally inherited in an autosomal dominant pattern, so a pathogenic variant can pass through any parent and affect people of any sex.

Testing is not just for women with breast cancer. BRCA2 can affect male breast, prostate, and pancreatic cancer risk. Lynch syndrome can raise colorectal and several extracolonic cancer risks in all sexes. APC-associated polyposis affects the colon and other organs regardless of sex.

A genetics professional can determine whether a focused single-gene test, a syndrome panel, or a broader hereditary cancer panel best matches the clinical question.

Three major syndrome patterns

BRCA1 and BRCA2

BRCA1 and BRCA2 help repair DNA damage. A germline pathogenic variant reduces a cell’s ability to maintain genomic stability and substantially raises the risk of certain cancers. The strongest associations involve breast and ovarian, fallopian tube, and primary peritoneal cancer. Depending on the gene, risk can also rise for male breast, prostate, pancreatic cancer, and melanoma.

BRCA1 and BRCA2 are not interchangeable. Age-specific risks, tumor characteristics, and the relative importance of prostate, pancreatic, or melanoma risk differ. Management therefore uses the exact gene, age, sex-related anatomy, family history, and personal preferences rather than the generic phrase “BRCA positive.”

A person inherits one altered copy in every cell. Cancer usually develops only after the remaining working copy is lost or impaired in a particular cell. This explains why the syndrome is inherited dominantly even though tumor formation often involves loss of both functional copies at the cellular level.

More detail is available in a BRCA1 and BRCA2 result guide.

Lynch syndrome

Lynch syndrome results from germline pathogenic variants in DNA mismatch repair genes MLH1, MSH2, MSH6, or PMS2, or certain EPCAM deletions that silence MSH2. It increases colorectal and endometrial cancer risk and can also affect the ovaries, stomach, small bowel, urinary tract, biliary tract, pancreas, prostate, brain, and sebaceous skin structures. The magnitude and timing of risk vary substantially by gene.

Lynch syndrome is not the same as “a family with colon cancer.” Nor does every mismatch repair-deficient tumor prove Lynch syndrome. Somatic changes confined to a tumor, MLH1 promoter methylation, and other mechanisms can create the same tumor phenotype. Germline testing and sometimes paired tumor analysis are needed to determine whether the finding is inherited.

A Lynch syndrome genetic test should include methods capable of detecting sequence variants and exon-level deletions or duplications; PMS2 requires particular care because of homologous pseudogenes.

APC-associated polyposis

A pathogenic APC variant can cause classic familial adenomatous polyposis, attenuated FAP, or certain gastric polyposis phenotypes. Classic FAP often produces hundreds to thousands of colorectal adenomas, frequently beginning in adolescence. Without effective surveillance and colectomy when indicated, colorectal cancer risk becomes extremely high. Attenuated FAP tends to involve fewer polyps and later cancer, but it still requires specialized care.

APC-related disease can also involve duodenal and gastric polyps, desmoid tumors, thyroid cancer, hepatoblastoma in young children, dental findings, retinal pigment changes, and other manifestations. The variant’s location can influence phenotype, but prediction is imperfect.

Not every person with multiple adenomas has APC-associated disease. MUTYH, POLE, POLD1, NTHL1, and other genes can cause overlapping phenotypes, and some polyposis remains genetically unexplained. Mosaic APC variants may be present at low levels or confined to certain tissues and can be missed in routine blood testing.

The APC genetic test guide explains classic, attenuated, and mosaic results in greater depth.

Choosing the right test

The test should be built around the question, not around the largest panel available.

Targeted familial testing is usually best when a relative has a documented pathogenic variant. The laboratory tests that exact change. A negative result can then be a true negative, meaning the person did not inherit the family’s identified risk variant.

Single-gene or syndrome testing may be appropriate when the phenotype is highly specific, such as a classic APC polyposis pattern or a family with a known Lynch syndrome gene. The test should include deletion/duplication analysis when relevant.

Multigene panel testing is often useful when cancer patterns overlap, the family is small, records are incomplete, or more than one syndrome could fit. Panels commonly include high-penetrance genes and moderate-risk genes. The tradeoff is a higher chance of finding a VUS or a gene with management guidance that is less certain.

RNA analysis may clarify selected splice variants or improve detection of variants that alter transcripts. It complements DNA testing rather than replacing it.

Mosaicism-aware testing may be needed when the phenotype is convincing but blood testing is negative, particularly in polyposis. Testing colon polyps, normal colon tissue, skin fibroblasts, or another specimen can sometimes identify an APC variant absent or low-level in blood.

Before testing, ask whether the laboratory analyzes full coding regions, splice boundaries, deletions and duplications, technically difficult regions, and known promoter variants where clinically relevant. Confirm whether it reports low-penetrance alleles and how those are distinguished from high-risk pathogenic variants.

Direct-to-consumer tests often examine only a small set of founder variants. A negative consumer result does not rule out other BRCA1/BRCA2 variants or other hereditary cancer genes. Any medically important positive result should be confirmed in a clinical laboratory using an independent specimen.

Panel size should not substitute for informed consent. A broad test can reveal risk for cancers unrelated to the original concern, recessive carrier status, or a pathogenic variant with limited evidence about management. Pretest counseling should cover what categories may be returned and whether the person can choose to limit certain findings.

Positive, negative, and VUS results

Pathogenic or likely pathogenic

A positive germline result identifies an inherited cancer-predisposition variant. “Likely pathogenic” generally carries the same clinical action as “pathogenic.” It does not prove cancer is present and does not state that cancer will definitely develop. Penetrance is incomplete, and risk depends on the gene, variant, age, sex-related organs, family history, exposures, and prior surgeries.

The next step is gene-specific management, not a generic “more screening” plan. The result may also affect current cancer treatment, such as eligibility for targeted therapy or surgical decisions, though treatment depends on the cancer and current guidelines.

Negative result

A true negative occurs when a known familial pathogenic variant was tested and not found. The person generally returns to screening based on personal history and non-genetic risk factors rather than the family’s identified syndrome.

An uninformative negative occurs when no family variant is known and a panel finds nothing explanatory. The family history may still indicate increased risk. The cause could be a variant the assay missed, a gene not tested or not yet discovered, shared environmental factors, or chance clustering.

A negative test in someone who had a narrow panel years ago may warrant updated testing. Panels, variant classification, and detection of copy-number or difficult regions have improved.

Variant of uncertain significance

A VUS is not a positive result. It means available evidence cannot determine whether the change disrupts gene function or is harmless. A VUS should not be used alone to recommend mastectomy, salpingo-oophorectomy, colectomy, or intensified screening. Care should continue based on personal and family history.

Healthy relatives usually should not receive predictive testing for a VUS outside a structured segregation study. Laboratories may ask for selected affected and unaffected relatives when their results could help classification, but this should be coordinated by genetics professionals.

Most VUS findings that are eventually reclassified become benign or likely benign. Keep contact information current with the ordering clinic and laboratory. Do not repeatedly retest the same VUS through consumer services; wait for formal evidence review.

The distinctions among these categories are explained further in a genetic variant result guide.

Germline versus tumor testing

Germline testing analyzes DNA intended to represent the person’s inherited genetic makeup, usually from blood or saliva. A germline pathogenic variant can be present in nearly every cell and can be passed to children.

Tumor testing analyzes changes in cancer cells. Most tumor variants are somatic, meaning they arose during the person’s life and are not inherited. Tumor profiling helps classify a cancer, select treatment, identify resistance, or estimate prognosis.

The two tests can intersect:

• A tumor may contain a BRCA1, BRCA2, mismatch repair, or APC variant that is also present in the germline.
• A tumor may have the same gene altered only somatically, with no inherited implication.
• Tumor sequencing may miss a germline variant because of assay design, tumor purity, filtering, or deletion detection.
• A negative tumor panel does not rule out hereditary risk when clinical criteria for germline testing are met.

Mismatch repair immunohistochemistry and microsatellite instability testing are screening tools for Lynch syndrome and treatment biomarkers. Loss of MLH1/PMS2 can result from somatic MLH1 promoter methylation, especially in colorectal or endometrial tumors. Loss of MSH2/MSH6, isolated MSH6 loss, or isolated PMS2 loss points toward different genes but still requires germline and sometimes tumor clarification. A detailed MSI and dMMR guide can help decode these patterns.

Blood is not always a perfect germline specimen in people with hematologic malignancies, prior bone marrow transplant, or age-related clonal hematopoiesis. A variant detected at an unexpected allele fraction may come from blood-cell clones rather than inherited DNA. Cultured skin fibroblasts or another validated specimen may be required.

When tumor-only testing reports a possible germline variant, confirm it through a clinical germline laboratory before testing relatives or making hereditary-risk decisions.

What a positive result can change

A pathogenic variant can alter surveillance, prevention, treatment, and family communication. The details should come from current syndrome-specific guidance.

For BRCA1/BRCA2, management may include earlier breast MRI and mammography, discussion of risk-reducing mastectomy, and risk-reducing removal of the fallopian tubes and ovaries at a gene- and age-appropriate time. Prostate and pancreatic surveillance may be considered for selected carriers. Ovarian screening with ultrasound or CA-125 has not been shown to replace risk-reducing surgery for those at sufficiently high risk.

For Lynch syndrome, regular colonoscopy begins earlier and occurs more frequently than average-risk screening. Depending on the gene and anatomy, care may address endometrial and ovarian risk, upper gastrointestinal surveillance, urinary tract considerations, skin examination, and other sites. Aspirin chemoprevention may be discussed with a clinician after weighing dose, bleeding risk, and individual factors.

For APC-associated polyposis, colon surveillance begins in childhood or adolescence in classic FAP. Polyp burden and cancer risk may eventually require colectomy. Upper gastrointestinal surveillance, thyroid evaluation, and management of desmoid disease or other manifestations are coordinated through an experienced center. Children of a carrier may need predictive testing before the age when surveillance begins.

Risk-reducing choices are personal. Age, prior cancer, fertility plans, menopause effects, surgical risk, body image, access, and competing health conditions matter. A positive result should lead to a shared decision process, not an automatic operation.

A person who already has cancer may receive treatment implications from the same result. BRCA-associated tumors can be relevant to PARP inhibitor use; mismatch repair-deficient cancers may respond to immune checkpoint therapy. These decisions depend on tumor type, stage, prior treatment, regulatory approval, and current oncology guidance.

Lifestyle measures such as not smoking, maintaining physical activity, limiting alcohol, and following general cancer-prevention recommendations remain useful but do not eliminate inherited risk. Gene-specific surveillance remains important even in a very healthy person.

Family testing and reproductive risk

Most high-penetrance hereditary cancer syndromes discussed here are autosomal dominant. A person with a germline pathogenic variant has a 50% chance of passing it in each pregnancy. The chance is the same for children of any sex and resets with every pregnancy.

Cascade testing begins with first-degree relatives—parents, siblings, and adult children—and then extends through the side of the family where the variant is found. Targeted testing for the exact familial variant is faster, less expensive, and more definitive than ordering a new broad panel for every relative.

A family letter can state:

• the gene and exact variant;
• the laboratory classification;
• the syndrome and major health implications;
• who in the family may be at risk;
• how to obtain targeted testing.

Testing children depends on when results change medical care. Predictive testing for APC is often offered during childhood because colon surveillance may begin in youth. Testing minors for adult-onset BRCA1/BRCA2 risk is generally deferred until they can participate in the decision and screening would begin. Lynch syndrome testing is usually timed to the earliest recommended surveillance or an unusually early family diagnosis.

Reproductive options include natural conception, prenatal diagnostic testing for the known familial variant, IVF with PGT-M, donor gametes, adoption, or conception without genetic testing. Prenatal and embryo testing are personal choices rather than routine requirements.

Some genes also have rare recessive implications when a child inherits pathogenic variants from both parents. Biallelic BRCA2 variants can cause Fanconi anemia; biallelic mismatch repair variants cause constitutional mismatch repair deficiency; biallelic APC variants are not the usual mechanism of FAP but specific inheritance questions may arise. Partner testing is not automatically required for every carrier, but it may be discussed when ancestry, consanguinity, family history, or reproductive goals make the recessive risk relevant.

A germline testing guide can help families understand why one person’s result has implications for relatives who have never had cancer.

Limits, privacy, and next steps

Genetic testing cannot predict the exact age a cancer will occur, guarantee that prevention will work, or explain every cancer cluster. Risk estimates are usually derived from groups and may not fit every ancestry or family. Guidelines also evolve as evidence accumulates.

Technical limits include deep intronic variants, low-level mosaicism, complex structural changes, regions affected by pseudogenes, and genes not included on the panel. Biological limits include unknown modifiers and phenocopies—cancers that occur in a hereditary family but are unrelated to the family variant.

Privacy protections vary by country and type of insurance. In the United States, federal law generally restricts health insurers and employers from using genetic information, but it does not provide the same protection for life, disability, or long-term care insurance. State law may add protections. People concerned about coverage should seek current legal or counseling guidance before testing.

After receiving a report, use this checklist:

1. Confirm that the result is germline and from a clinical laboratory.
2. Record the exact gene, transcript, variant, and classification.
3. Ask whether the result explains the personal and family cancer pattern.
4. Obtain a written gene-specific screening and prevention plan.
5. Discuss treatment implications with oncology if cancer is present.
6. Identify relatives eligible for targeted testing.
7. Keep a copy of the original report and family letter.
8. Ask how the clinic handles VUS reclassification and guideline updates.
9. Revisit testing if the original panel was narrow or the family history changes.

Do not delay evaluation of a breast mass, rectal bleeding, unexplained anemia, abnormal uterine bleeding, persistent abdominal symptoms, or another concerning sign while waiting for genetic testing. A hereditary-risk result guides prevention; it does not replace ordinary diagnostic care.

The most useful outcome is not simply a laboratory label. It is a coordinated plan that connects the exact gene to current screening, prevention, cancer treatment when relevant, and informed choices for relatives.

References

• Genetic Testing Fact Sheet 2024
• BRCA Gene Changes: Cancer Risk and Genetic Testing 2024
• Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline 2024 (Guideline)
• BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer 2025 (Review)
• Lynch Syndrome 2021 (Review)
• APC-Associated Polyposis Conditions 2022 (Review)

Disclaimer

This article provides general education and does not replace individualized cancer-risk assessment, genetic counseling, oncology care, or screening guidance. Recommendations depend on the exact gene and variant, age, anatomy, personal cancer history, family history, and current professional guidelines. Do not make preventive surgery, treatment, or family-testing decisions from a VUS or tumor-only result without specialist review.